AMLX

Amylyx Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 2/10
  • Value↑ 5/10
Amylyx Pharmaceuticals sales and earnings growth
AMLX Growth
Fair
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↑ 65.46%
  • FCF Y/Y↑ 26.41%
Amylyx Pharmaceuticals gross and profit margin trends
AMLX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -93.64%
Amylyx Pharmaceuticals net debt vs free cash flow
AMLX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Amylyx Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗